|
|
难治性免疫性血小板减少症与T细胞相关的机制
|
Abstract:
难治性免疫性血小板减少症经过一、二线药物治疗均无效，或脾切除无效/术后复发。难治性患者血小板计数低，出血风险高，常规治疗手段效果有限，其机制尚不清楚。本文从T细胞的通路、异常活化及受体三方面展开，通路方面我们发现T细胞的特异性克隆导致细胞毒性增加，并触发血小板活化和凋亡，甲基化诱导一些敏感基因的表达，导致免疫的失衡，使得基因下游的细胞因子释放异常，从而影响血小板的增殖及凋亡，MDSC (髓源性抑制细胞)会释放一些抑制性配体阻碍T细胞的增殖，挽救LKB1-AMPK信号通路分子和抑制性细胞因子的表达缺陷，增强了T细胞增殖。T细胞异常活化导致一些细胞因子的持续表达或相对消除，致使对一线治疗无反应。受体方面发现CD8+ T细胞毒性高的人群中Neu1易位程度高，抗GPIb/IX抗体似乎会导致更多的血小板凋亡，抑制其活性，血小板的唾液酸化会减少。通过这三方面来总结导致难治性ITP可能发生的机制，为诊断难治性ITP的新型标志物或为治疗靶点提供更多的信息。
Refractory immune thrombocytopenia is ineffective after first- and second-line drug therapy, or splenectomy is ineffective/relapsed after surgery. Refractory patients have low platelet counts, high bleeding risk, and limited response to conventional treatments, and the mechanism is unclear. This article focuses on the pathways, abnormal activation, and receptors of T cells. In this paper, we found that the specific cloning of T cells leads to increased cytotoxicity and triggers platelet activation and apoptosis, methylation induces the expression of some sensitive genes, resulting in an imbalance of immunity, which makes the cytokine release downstream of genes abnormal, thereby affecting the proliferation and apoptosis of platelets, and MDSCs (myeloid-derived suppressor cells) will release some inhibitory ligands to hinder the proliferation of T cells and rescue LKB1-AMPK Defective expression of signaling pathway molecules and inhibitory cytokines enhances T cell proliferation. Aberrant T cell activation results in sustained expression or relative elimination of some cytokines, resulting in non-response to first-line therapy. In terms of receptors, it was found that the degree of Neu1 translocation was high in people with high CD8+ T cytotoxicity, and anti-GPIb/IX antibodies appeared to cause more platelet apoptosis, inhibit their activity, and reduce platelet sialylation. Through these three aspects, we summarize the mechanisms that may lead to the occurrence of refractory ITP, and provide more information for new markers for diagnosing refractory ITP or for therapeutic targets.
| [1] | Zufferey, A., Kapur, R. and Semple, J. (2017) Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). Journal of Clinical Medicine, 6, Article 16. https://doi.org/10.3390/jcm6020016 |
| [2] | 梅恒, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J]. 临床内科杂志, 2021, 38(6): 431-432. |
| [3] | Arnold, D.M., Clerici, B., Ilicheva, E. and Ghanima, W. (2023) Refractory Immune Thrombocytopenia in Adults: Towards a New Definition. British Journal of Haematology, 203, 23-27. https://doi.org/10.1111/bjh.19075 |
| [4] | Vianelli, N., Auteri, G., Buccisano, F., Carrai, V., Baldacci, E., Clissa, C., et al. (2022) Refractory Primary Immune Thrombocytopenia (ITP): Current Clinical Challenges and Therapeutic Perspectives. Annals of Hematology, 101, 963-978. https://doi.org/10.1007/s00277-022-04786-y |
| [5] | Schifferli, A., Le Gavrian, G., Aladjidi, N., Moulis, G., Godeau, B. and Kühne, T. (2023) Chronic Refractory Immune Thrombocytopenia in Adolescents and Young Adults. British Journal of Haematology, 203, 36-42. https://doi.org/10.1111/bjh.19081 |
| [6] | Semple, J., Milev, Y., Cosgrave, D., Mody, M., Hornstein, A., Blanchette, V., et al. (1996) Differences in Serum Cytokine Levels in Acute and Chronic Autoimmune Thrombocytopenic Purpura: Relationship to Platelet Phenotype and Antiplatelet T-Cell Reactivity. Blood, 87, 4245-4254. https://doi.org/10.1182/blood.v87.10.4245.bloodjournal87104245 |
| [7] | Malik, A., Sayed, A.A., Han, P., Tan, M.M.H., Watt, E., Constantinescu-Bercu, A., et al. (2023) The Role of CD8+ T Cell Clones in Immune Thrombocytopenia. Blood, 141, 2417-2429. https://doi.org/10.1182/blood.2022018380 |
| [8] | Yazdanbakhsh, K., Provan, D. and Semple, J.W. (2023) The Role of T Cells and Myeloid-Derived Suppressor Cells in Refractory Immune Thrombocytopenia. British Journal of Haematology, 203, 54-61. https://doi.org/10.1111/bjh.19079 |
| [9] | Türk, L., Filippov, I., Arnold, C., Zaugg, J., Tserel, L., Kisand, K., et al. (2024) Cytotoxic CD8+ Temra Cells Show Loss of Chromatin Accessibility at Genes Associated with T Cell Activation. Frontiers in Immunology, 15, Article 1285798. https://doi.org/10.3389/fimmu.2024.1285798 |
| [10] | Liu, S. and Shan, N. (2020) DNA Methylation Plays an Important Role in Immune Thrombocytopenia. International Immunopharmacology, 83, Article ID: 106390. https://doi.org/10.1016/j.intimp.2020.106390 |
| [11] | Chen, Z., Guo, Z., Ma, J., Ma, J., Liu, F. and Wu, R. (2014) Foxp3 Methylation Status in Children with Primary Immune Thrombocytopenia. Human Immunology, 75, 1115-1119. https://doi.org/10.1016/j.humimm.2014.09.018 |
| [12] | Du, H., Tang, Q., Yang, J., Yan, B., Yang, L. and Wang, M. (2023) Genome-Wide DNA Methylation Profiling of CD4+ T Lymphocytes Identifies Differentially Methylated Loci Associated with Adult Primary Refractory Immune Thrombocytopenia. BMC Medical Genomics, 16, Article No. 124. https://doi.org/10.1186/s12920-023-01557-0 |
| [13] | Liu, S., Qu, H., Sun, R., Yuan, D., Sui, X. and Shan, N. (2022) High-Throughput DNA Methylation Analysis in ITP Confirms NOTCH1 Hypermethylation through the Th1 and Th2 Cell Differentiation Pathways. International Immunopharmacology, 111, Article ID: 109105. https://doi.org/10.1016/j.intimp.2022.109105 |
| [14] | Han, P., Yu, T., Hou, Y., Zhao, Y., Liu, Y., Sun, Y., et al. (2021) Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia. Frontiers in Immunology, 12, Article 630693. https://doi.org/10.3389/fimmu.2021.630693 |
| [15] | Wang, L., Wang, H., Zhu, M., Ni, X., Sun, L., Wang, W., et al. (2024) Platelet-Derived TGF-Β1 Induces Functional Reprogramming of Myeloid-Derived Suppressor Cells in Immune Thrombocytopenia. Blood, 144, 99-112. https://doi.org/10.1182/blood.2023022738 |
| [16] | Ni, X., Wang, L., Wang, H., Yu, T., Xie, J., Li, G., et al. (2022) Low-Dose Decitabine Modulates Myeloid-Derived Suppressor Cell Fitness via LKB1 in Immune Thrombocytopenia. Blood, 140, 2818-2834. https://doi.org/10.1182/blood.2022016029 |
| [17] | Ma, L., Simpson, E., Li, J., Xuan, M., Xu, M., Baker, L., et al. (2015) CD8+ T Cells Are Predominantly Protective and Required for Effective Steroid Therapy in Murine Models of Immune Thrombocytopenia. Blood, 126, 247-256. https://doi.org/10.1182/blood-2015-03-635417 |
| [18] | Stimpson, M.L., Lait, P.J.P., Schewitz-Bowers, L.P., Williams, E.L., Thirlwall, K.F., Lee, R.W.J., et al. (2020) IL-10 and IL-17 Expression by CD4+ T Cells Is Altered in Corticosteroid Refractory Immune Thrombocytopenia (ITP). Journal of Thrombosis and Haemostasis, 18, 2712-2720. https://doi.org/10.1111/jth.14970 |
| [19] | Mann, E.H., Gabryšová, L., Pfeffer, P.E., O’Garra, A. and Hawrylowicz, C.M. (2019) High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17+IL-10+ Memory CD4+ T Cell Response Towards a Single Il-10-Producing Phenotype. The Journal of Immunology, 202, 684-693. https://doi.org/10.4049/jimmunol.1800697 |
| [20] | McGeachy, M.J., Bak-Jensen, K.S., Chen, Y., Tato, C.M., Blumenschein, W., McClanahan, T., et al. (2007) TGF-β and IL-6 Drive the Production of IL-17 and IL-10 by T Cells and Restrain TH-17 Cell-Mediated Pathology. Nature Immunology, 8, 1390-1397. https://doi.org/10.1038/ni1539 |
| [21] | Qiu, J., Liu, X., Li, X., Zhang, X., Han, P., Zhou, H., et al. (2016) CD8+ T Cells Induce Platelet Clearance in the Liver via Platelet Desialylation in Immune Thrombocytopenia. Scientific Reports, 6, Article No. 27445. https://doi.org/10.1038/srep27445 |
| [22] | Zheng, S.S., Ahmadi, Z., Leung, H.H.L., Wong, R., Yan, F., Perdomo, J.S., et al. (2022) Antiplatelet Antibody Predicts Platelet Desialylation and Apoptosis in Immune Thrombocytopenia. Haematologica, 107, 2195-2205. https://doi.org/10.3324/haematol.2021.279751 |
